You are here
Dr Kirsten Perrett
Dr Kirsten Perrett is a consultant paediatrician with specialty training in vaccinology and allergy. She is a Monash Medical Graduate and completed her paediatric training at the Royal Children's Hospital (RCH). Dr Perrett gained clinical vaccine trials experience with the Oxford Vaccine Group, University of Oxford and the Vaccine and Immunisation Research Group (VIRGo) at Murdoch Childrens, which she joined in 2012.
She completed her PhD in 2012 with The University of Melbourne in collaboration with The University of Oxford, earning herself a Dean's Award. Dr Perrett currently holds a National Health and Medical Research Council Early Career Fellowship and an MCRI Career Development Award. She is an Honorary Fellow with the School of Population and Global Health, University of Melbourne and has clinical roles in immunisation and allergy at the RCH.
Dr Perrett was a Visiting Scholar with the Stanford Lucille-Packard Children's Hospital Vaccine Program, Stanford University in 2013-14.
- 2013: Dean's Award for Excellence in a PhD thesis, University of Melbourne
- 2013: Early Career Fellowship, Health Professional, National Health and Medical Research Council
- 2013: Career Development Award, Murdoch Childrens Research Institute
Dr Kirsten Perrett's research involves clinical trials of new or improved vaccines, vaccine schedules or vaccine combinations for children and adults. In particular, she has focused on the immune response, immunological memory and persistence of immunity to vaccines against the meningococcus and Hib (encapsulated bacteria).
Her current research interests include clinical trials on new vaccines against meninogocccal serogroup B and meningococcal carriage. In addition, she has a strong interest in maternal vaccination for the prevention of early infant disease.
- Antibody persistence in Australian adolescents following meningococcal C conjugate vaccination
- Kinetics of the immune response to a recombinant, four-component, meningococcal serogroup B vaccine in adolescents
- Meningococcal carriage in Australian adolescents
- Safety and Immunogenicity of pertussis vaccination in pregnancy
- Effectiveness of maternal influenza vaccination in prevention of influenza in early infancy
PERRETT KP, John TM, Winter AP, Jin C, Kibwana E, Yu LM, Curtis N, Pollard AJ. Long-term persistence of immunity and B-cell memory following Haemophilus influenzae type b conjugate vaccine in early childhood and response to booster. Clinical Infectious Diseases. published online January 7, 2014
PERRETT KP, Nolan TJ, McVernon. Haemophilus influenzae type b – Serogroup C and Y meningococcal conjugate vaccine (HibMenCY) for the prevention of meningococcal disease. Infectious Diseases and Therapy. 2013 June, 2(1): 1-13
PERRETT KP, Jin C, Clutterbuck E, John TM, Winter AP, Kibwana E, Yu LM, Curtis N, Pollard AJ. B-cell memory to serogroup C meningococcal conjugate vaccine in childhood and response to booster: little association with serum IgG antibody . Journal of Immunology. 2012 August, 189(5): 2673-81
Moore, CE, Hennig BJ, PERRETT KP, Hoe C, Lee SJ, Fletcher H, Brocklebank D, O'Connor D, Snape MD, Hall AJ, Segal S, Hill AVS, Pollard AJ. SNPs in the TL3 and CD44 genes are associated with persistence of vaccine-induced immunity to serogroup C meningococcal conjugate vaccine. Clinical Vaccine Immunology. 2012 March, 19(3): 295-303
Clifford, V, Crawford, NW, Royle, J, Lazzaro, T, Danchin, M, PERRETT KP, Lee, KJ, Buttery, JP. Recurrent apnoea post immunization: Informing re-immunisation policy. Vaccine. 2011 August, 29(34): 5681-5687
PERRETT KP, Winter AP, Kibwana E, Jin C, John TM, Yu LM, Borrow R, Curtis N, Pollard AJ. Antibody persistence after serogroup C meningococcal conjugate immunisation of United Kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial. Clinical Infectious Diseases. 2010 June, 50(12): 1601-10
Kelly D; Snape MD; PERRETT KP; Clutterbuck E; Blanchardrohner G; Jones M; Yu LM; Pollard AJ. Plasma and memory B-cell kinetics in infants following a primary schedule of CRM197 conjugated serogroup C meningococcal polysaccharide vaccine. Immunology. 2009 May, 127(1): 134-143
Pollard AJ, PERRETT KP, Beverley PC. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nature Reviews Immunology. 2009 March, 9: 213-220
PERRETT KP, Snape MD, Ford KJ, John TM, Yu L, Langley, Mcneil S, Dull P, Ceddia F, Anemona A, Halperin SA, Dobson S, Pollard AJ . Safety, immunogenicity and immune memory of a non-adjuvanted tetravalent meningococcal glycoconjugate vaccine in healthy infants. Paediatric Infectious Diseases Journal. 2009 March, 28(3): 186-193.